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Abstract: Pulmonary artery pressure elevation complicates the course of many complex 
disorders treated in a noncardiac intensive care unit. Acute pulmonary hypertension, however, 
remains underdiagnosed and its treatment frequently begins only after serious complications 
have developed. Signiﬁ  cant pathophysiologic differences between acute and chronic pulmonary 
hypertension make current classiﬁ  cation and treatment recommendations for chronic pulmonary 
hypertension barely applicable to acute pulmonary hypertension. In order to clarify the 
terminology of acute pulmonary hypertension and distinguish it from chronic pulmonary 
hypertension, we provide a classiﬁ  cation of acute pulmonary hypertension according to 
underlying pathophysiologic mechanisms, clinical features, natural history, and response to 
treatment. Based on available data, therapy of acute arterial pulmonary hypertension should 
generally be aimed at acutely relieving right ventricular (RV) pressure overload and preventing 
RV dysfunction. Cases of severe acute pulmonary hypertension complicated by RV failure and 
systemic arterial hypotension are real clinical challenges requiring tight hemodynamic monitoring 
and aggressive treatment including combinations of pulmonary vasodilators, inotropic agents 
and systemic arterial vasoconstrictors. The choice of vasopressor and inotropes in patients 
with acute pulmonary hypertension should take into consideration their effects on vascular 
resistance and cardiac output when used alone or in combinations with other agents, and must 
be individualized based on patient response.
Keywords: acute pulmonary hypertension, pulmonary hypertension, acute cor pulmonale, cor 
pulmonale, right heart failure
Introduction
Many complex medical disorders managed in the intensive care unit (ICU) are associ-
ated with an elevation of pulmonary arterial pressure (PAP). Usually this is transient, 
of mild to moderate severity and not considered to affect patient outcome. However, in 
some circumstances serious and prolonged elevation of PAP progresses to severe acute 
pulmonary hypertension, leading to life threatening complications including refractory 
systemic arterial hypotension, severe hypoxemia, right ventricular (RV) dysfunction 
and failure and ultimately resulting in cardiogenic and/or obstructive shock and death. 
Unfortunately, in most cases acute pulmonary hypertension remains under diagnosed 
and its treatment begins only after serious complications have developed.
It is well known that left ventricular dysfunction/failure is one of the main causes 
of pulmonary venous hypertension, particularly in the cardiac ICU setting (McNeil 
et al 2003). However, this review is focused on the pathophysiology, monitoring and 
management of the acute and acute on chronic arterial pulmonary hypertension treated 
in the noncardiac ICU.
Deﬁ  nition of arterial pulmonary hypertension
Pulmonary hypertension is characterized by elevated PAP and secondary RV failure. 
The currently accepted clinical classiﬁ  cation of pulmonary hypertension (World Health Vascular Health and Risk Management 2008:4(5) 1044
Tsapenko et al
Organization [WHO] Venice 2003) distinguishes ﬁ  ve main 
types of the condition (Table 1) (Galie et al 2004). However, 
this classiﬁ  cation of sustained (chronic) pulmonary hyperten-
sion is less applicable in acute settings. In order to clarify 
the terminology of acute pulmonary hypertension and distin-
guish it from chronic pulmonary hypertension, we provide a 
classiﬁ  cation of acute pulmonary hypertension according to 
underlying pathophysiologic mechanisms, clinical features, 
natural history, and response to treatment (Table 2).
Chronic pulmonary arterial hypertension (PAH) is deﬁ  ned 
by a mean pulmonary arterial pressure (PAP)  25 mmHg at 
rest or  30 mmHg with exercise, associated with a pulmo-
nary capillary wedge pressure (PCWP)  15 mmHg and pul-
monary vascular resistance (PVR)  3 mmHg/l/min (Wood 
units) measured by right heart catheterization. It is considered 
to be severe if mean PAP  45 mm Hg; of moderate severity, 
if mean PAP 35–45 mm Hg or mild, if mean PAP  35 mm 
Hg. Despite clinical and pathophysiologic differences among 
different kinds of pulmonary hypertension, it is widely 
accepted to apply mean PAP deﬁ  nitions developed for PAH 
to other types of pulmonary hypertension.
Cor pulmonale is the most important consequence of 
pulmonary hypertension and remains a frequent cause of RV 
failure and death in patients with arterial pulmonary hyper-
tension in the ICU. Cor pulmonale is deﬁ  ned as a change in 
structure and function of the RV, which develops as a result of 
a respiratory disorder or other abnormalities in the pulmonary 
circulation system. Almost all diseases manifested by arterial 
pulmonary hypertension can cause cor pulmonale: either as an 
acute condition, if the arterial pulmonary hypertension devel-
ops acutely (as with sepsis/acute lung injury [ALI], pulmonary 
embolism [PE], cardiac surgery, drug-induced, etc), or as a 
Table 1 Clinical classiﬁ  cation of pulmonary hypertension –   Venice 2003
1. Pulmonary arterial hypertension (PAH)
  1.1. Idiopathic (IPAH)
  1.2. Familial (FPAH)
  1.3. Associated with (APAH):
  1.3.1. Connective tissue disease
  1.3.2. Congenital systemic to pulmonary shunts
  1.3.3. Portal hypertension
  1.3.4. HIV infection
  1.3.5. Drugs and toxins
  1.3.6. Other (thyroid disorders, glycogen storage disease, Gaucher’s disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, 
myeloproliferative disorders, splenectomy)
 1.4.    Associated with signiﬁ  cant venous or capillary involvement
  1.4.1. Pulmonary veno-occlusive disease (PVOD)
  1.4.2. Pulmonary capillary hemangiomatosis (PCH)
  1.5. Persistent pulmonary hypertension of the newborn (PPHN)
2. Pulmonary hypertension associated with left heart diseases
  2.1. Left-sided atrial or ventricular heart disease
  2.2. Left-sided valvular heart disease
3. Pulmonary hypertension associated with lung respiratory diseases and/or hypoxia
  3.1. Chronic obstructive pulmonary disease
  3.2. Interstitial lung disease
  3.3. Sleep disordered breathing
 3.4.    Alveolar hypoventilation disorders
  3.5. Chronic exposure to high altitudes
  3.6. Developmental abnormalities
4. Pulmonary hypertension due to chronic thrombotic and/or embolic disease
  4.1. Thromboembolic obstruction of proximal pulmonary arteries
  4.2. Thromboembolic obstruction of distal pulmonary arteries
  4.3. Nonthrombotic pulmonary embolism (tumor, parasites, foreign material)
5. Miscellaneous (Sarcoidosis, histiocytosis X, lymphangiomatosis, compression of pulmonary vessels (adenopathy, tumor, ﬁ  brosing mediastinitis)Vascular Health and Risk Management 2008:4(5) 1045
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chronic condition, if arterial pulmonary hypertension is mainly 
chronic (as in chronic obstructive pulmonary disease (COPD), 
interstitial lung disease (ILD), sleep disorder breathing, 
chronic hypoventilation, PAH, chronic thromboembolic pul-
monary hypertension/CTEPH, portopulmonary hypertension 
etc). Increased RV afterload leads to RV dilatation in most 
acute cases of cor pulmonale when there is not enough time 
for adaptive mechanisms (eg, RV hypertrophy) to develop. 
Thus, RV dilatation or RV hypertrophy are the main features 
of the acute and chronic cor pulmonale, respectively.
Pathophysiology of pulmonary 
hypertension
Pathological changes in each segment of the pulmonary 
vasculature (precapillary arteries and arterioles, capillary 
beds, and postcapillary pulmonary veins and venules). 
can lead to the development of pulmonary hypertension. 
Pulmonary venous and capillary hypertension typically 
results from left ventricular (LV) diastolic dysfunction, 
valvular heart disease, or rarely, pulmonary venous 
disorders. The mechanisms of arterial pulmonary hyper-
tension include vascular thromboembolism, endothelial 
dysfunction, (hypoxic) vasoconstriction, pulmonary vascular 
remodeling, smooth muscle proliferation with or without 
neointimal formation and in situ thrombosis (Humbert et al 
2004). Endothelial dysfunction with an imbalance between 
vasodilation and vasoconstriction, and between apoptosis 
and proliferation is thought to play a pivotal role in the 
development of chronic progressive PAH. Hypoxemic 
pulmonary vasoconstriction is an important determinant of 
arterial pulmonary hypertension in patients with respiratory 
disorders (Humbert et al 2004). In many types of pulmonary 
hypertension production of endogenous vasodilators (nitric 
oxide [NO] and prostacyclin) is impaired and production of 
vasoconstrictors (endothelin-1) is increased (Humbert et al 
2004). This forms the pathophysiologic basis of common 
treatment strategies for arterial pulmonary hypertension 
which attempt to achieve balance in key molecular pathways 
by increasing available NO and prostacyclin, or reducing the 
effects of endothelin-1.
Acute arterial pulmonary hypertension is characterized 
by a sudden increase in PAP. Mechanical obstruction 
with subsequent vasoconstriction characterizes acute 
pulmonary hypertension in PE. In ALI/acute respiratory 
distress syndrome (ARDS), both hypoxic pulmonary 
vasoconstriction and accumulation of intravascular ﬁ  brin 
and cellular debris contribute to subsequent vascular oblit-
eration and pulmonary hypertension (Moloney and Evans 
2003). Endotoxin plays a signiﬁ  cant role in the develop-
ment of pulmonary hypertension during sepsis. Multiple 
animal studies have shown that endotoxin can cause not 
only systemic hypotension, but also pulmonary biphasic 
hypertension, along with a decrease in compliance and an 
increase in resistance of respiratory system (Albertini et al 
2001). Endotoxin-dependent hemodynamic and respiratory 
effects are mediated by excessive release of inﬂ  ammatory 
mediators and imbalances in production of NO, prostanoids, 
and endothelin-1 (ET-1) (Wort and Evans 1999; Albertini 
et al 2001). Pulmonary hypertension in endotoxemia is 
characterized by constriction of proximal pulmonary arteries 
during the early phase followed by decreased compliance 
of the distal pulmonary vasculature (Lambermont et al 
1999). Endotoxin infusion can dramatically affect RV 
function: in the very early phase of endotoximic shock, 
RV-vascular coupling is preserved by an increase in RV 
contractility. Later, myocardial oxygen consumption and 
energy cost of RV contractility are increased, which along 
with progressive endotoxin-induced pulmonary hypertension 
lead to RV dysfunction and failure (Lambermont et al 
2003). Maintenance of appropriate coronary perfusion is 
therefore an important therapeutic consideration during 
septic shock.
Neurohormonal activation is an important factor in both 
acute and chronic RV failure. The consequence of sympa-
thetic hyperactivity is an increase in pulmonary vascular 
resistance (PVR) with impedance of ﬂ  ow, causing RV strain 
that impairs ﬁ  lling and causes RV volume and pressure 
overload. The RV dilates (and eventually hypertrophy 
Table 2 Pulmonary hypertension in the intensive care unit
• Acute and acute-on-chronic venous pulmonary hypertension
Pulmonary hypertension secondary to left ventricular dysfunction/failure 
with left atrial hypertension
  – CHF, acute MI, diastolic dysfunction, severe valvular disease (MR, MS, etc)
  – Pulmonary venoocclusive disease (VOD)
• Acute-on-chronic arterial pulmonary hypertension
Worsening of preexisting pulmonary hypertension, usually with 
respiratory or cardiovascular decompensation either as
  – Natural progression or
  – Precipitated by acute condition (such as sepsis/ARDS, PE, drugs etc)
• Acute arterial pulmonary hypertension
Without preexisting pulmonary hypertension
  – Massive PE
  – ARDS, sepsis, drug-induced, etc.
Abbreviations: ARDS, acute respiratory distress syndrome;  CHF, chronic heart fail-
ure; MI, myocardial infection; MR, mitral regurgitation; MS, mitral stenosis; PE, pulmonary 
embolism;  VOD, pulmonary veno-occlusive disease.Vascular Health and Risk Management 2008:4(5) 1046
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can develop in chronic gradual pulmonary hypertension), 
encroaching on the LV and decreasing preload, cardiac 
output, and coronary perfusion. Increased RV wall stress 
results in RV ischemia (Via and Braschi 2004). Tricuspid 
regurgitation develops as a result of RV dysfunction and 
portends a poor prognosis (Nath et al 2004). RV systolic 
dysfunction, severe tricuspid regurgitation, arrhythmias, and 
LV dysfunction caused by ventricular interdependence may 
contribute to low cardiac output and hypotension in patients 
with pulmonary hypertension. Regardless of the underlying 
cause of pulmonary hypertension, the ﬁ  nal common pathway 
for hemodynamic deterioration and death is cor pulmonale 
and RV failure. Among other clinically important adverse 
effects of right heart failure is the development of systemic 
venous hypertension leading to concomitant visceral organ 
congestion and dysfunction.
It is important to emphasize the difference between the 
ability of RV to adapt to sudden (acute) vs gradual (chronic) 
elevation of PAP. The normal RV can acutely adapt to high 
ﬂ  ow, but is not able to tolerate any but very short acute high 
pressure load (Blaise et al 2003). The normal RV cannot 
acutely increase and sustain mean PAP   40 mm Hg for 
more than a brief period of time (Chin et al 2005).
Common causes of arterial 
pulmonary hypertension
in noncardiac ICU
Acute on chronic arterial pulmonary 
hypertension
Patients with preexisting pulmonary hypertension (ie, acute 
on chronic arterial pulmonary hypertension) are particularly 
vulnerable to acute illnesses, which commonly result in 
rapid deterioration and even death (Hoeper et al 2002). 
Besides PAH several other conditions are associated with 
chronic arterial pulmonary hypertension including interstitial 
lung diseases, COPD, chronic hypoventilation and sleep 
disorder breathing, portopulmonary hypertension and 
chronic pulmonary thromboembolism. Multiple predisposing 
factors (Table 3) can precipitate acute on chronic pulmonary 
hypertension and cor pulmonale and lead to adverse outcome 
in patients with preexisting chronic arterial pulmonary 
hypertension.
Patients with chronic pulmonary arterial hypertension 
can rapidly deteriorate and usually die from progressive 
RV failure (49%), progressive respiratory failure (18%), or 
sudden cardiac death (17%). Cardiopulmonary resuscitation 
(CPR), even when attempted in the hospital setting is rarely 
successful. Only 6% patients survived for more than 90 days 
and most survivors had identiﬁ  able causes of circulatory 
arrest that were rapidly reversible. The pulmonary blood ﬂ  ow 
is virtually absent in these patients during CPR (Hoeper et al 
2002). Interestingly, hemodynamic measurements obtained 
within 3 month before CPR did not reveal any signiﬁ  cant 
differences between the survivors and non survivors. In 54%, 
cardiorespiratory arrest was associated with an intercurrent 
illness (Hoeper et al 2002), illustrating how preexisting 
pulmonary hypertension adversely affects patients’ compen-
satory capacity and ability to survive an acute illness.
Acute arterial pulmonary hypertension
Massive PE, sepsis, and ALI are the main causes of acute 
arterial pulmonary hypertension in the adult patient popula-
tion (Vieillard-Baron et al 2001b).
Massive pulmonary embolism
Massive PE involving at least two lobar arteries is the most 
important cause of acute cor pulmonale developing in 61% 
of patients with massive PE. The mortality ranges from 3% in 
hemodynamically stable patients to 59% in unstable patients 
(Kasper et al 1997; Vieillard-Baron et al 2001a).
Hemodynamic instability in a setting of PE is deﬁ  ned 
as systolic blood pressure (SBP)  90 mmHg or a drop in 
Table 3 Factors predisposing to adverse outcome in patients with 
preexisting pulmonary hypertension
• Pulmonary:
  – Chronic hypoxia, predisposition to hypoxic respiratory failure;
  – Restrictive lung disease (with or w/o COPD);
  – Decreased DLCO;
  – Decreased pulmonary compensatory capacity.
• Cardiovascular:
  – Pulmonary arterial hypertension (with or w/o venous component);
  – Increased right to left shunting;
  – Right ventricular strain, predisposition to right ventricular failure;
  – Systemic use of vasoactive agents;
  – RV hyperthrophy, requiring higher RV preload
  – Decreased compensatory capacity.
• Response to infection:
  – Use of immunosuppressive, disease modifying drugs for underlying 
disease;
  – Malnutrition and overall decreased functional reserve
• Visceral congestion:
  – As a result of RV failure. Predisposes to multiorgan failure.
Abbreviations: COPD, chronic obstructive pulmonary disease; DLCO, diffusing 
capacity of the lung for carbon monoxide; RV, right ventricle.Vascular Health and Risk Management 2008:4(5) 1047
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SBP  40 mmHg from baseline for more then 15 minutes, 
which is not otherwise explained by hypovolemia, sepsis, 
or new arrhythmia (Kasper et al 1997) The degree of shock 
inferred from the presence of metabolic acidosis, but not 
TTE (TransThoracic ECHO) ﬁ  ndings is the most powerful 
predictor of death in these patients (Vieillard-Baron et al 
2001a, 2002).
Acute respiratory distress syndrome
and sepsis
The onset of acute cor pulmonale as a complication of ALI 
and its more severe form, ARDS, is more gradual than in 
patients with massive PE. It usually occurs at least 48 hours 
after the beginning of respiratory support (Vieillard-Baron 
et al 2001b).
Evaluation of RV function by TEE (TransEsophageal 
ECHO) in a group of 75 ARDS patients submitted to 
protective ventilation demonstrated 25% incidence of acute 
RV dysfunction, with detrimental hemodynamic consequences 
associated with tachycardia. However, those changes in heart 
function were reversible in patients who recovered and did 
not increase mortality (Vieillard-Baron et al 2001b). Although 
the initial magnitude of pulmonary hypertension was not an 
indicator of mortality, PAP further increased in nonsurvivors, 
but not in survivors when followed for 7 days (Leeman 1999). 
Thus, development of the pulmonary hypertension in ARDS 
patients seems to be a sign of poor prognosis. In a cohort 
of 352 ARDS patients both mortality rate and incidence of 
cor pulmonale were related to the level of plateau pressure 
during mechanical ventilation. An interaction between plateau 
pressure and cor pulmonale was observed whereas odds ratio 
of dying for an increase in plateau pressure (from 18–26 to 
27–35 cm H2O) in patients without cor pulmonale was 1.05 
(p = 0.635), in contrast to odds ratio of 3.32 (p   0.034) in 
patients with cor pulmonale (Jardin and Vieillard-Baron 2007). 
The implementation of low tidal volume ventilation in patients 
with ARDS has signiﬁ  cantly lowered not only mortality (down 
to 32%), but also incidence of acute cor pulmonale in this 
patient population (Vieillard-Baron et al 2001b).
In addition to being the major risk factor for ARDS 
development, sepsis itself can sometimes lead to severe acute 
arterial pulmonary hypertension (Sibbald et al 1978).
Intra- and post-surgical pulmonary hypertension
Some surgical interventions, in particular vascular, cardiac 
and thoracic surgery may cause acute elevation of PAP either 
during the surgery or shortly after the intervention has been 
completed. This is particularly dangerous in patients with 
preexisting pulmonary hypertension, since even short periods 
of RV pressure overload can lead to profound decompensation 
with all negative hemodynamic consequences. Preexisting 
pulmonary hypertension is one of the major risk factors for 
morbidity and mortality in cardiothoracic surgery patients 
(Bernstein and Parsonnet 2000). Pulmonary hypertension is 
a major determinant of perioperative morbidity and mortality 
in special situations such as heart and lung transplantation, 
pneumonectomy, and ventricular assist device placement 
(Subramaniam and Yared 2007).
Airway manipulations and some induction agents can 
precipitate an acute increase in PVR (Hickey and Retzack 
1993; Hohn et al 1999). At the same time sedative/anesthetic 
drugs can decrease ventricular contractility (eg, barbiturates, 
propofol) or decrease SVR (eg, propofol) negatively affecting 
systemic and coronary perfusion pressure. All this can cause 
severe circulatory collapse, particularly in patients with 
preexisting pulmonary hypertension (Hohn et al 1999). It 
is believed that an elevated PAP during and after surgery 
develops secondary to acute left heart failure/dysfunction 
or can be a consequence of pulmonary parenchymal and 
endothelial injury with activation of the systemic and 
pulmonary inflammatory response to cardiopulmonary 
bypass circulation and/or ischemia-reperfusion (Wynne 
and Botti 2004). Protamine-mediated acute pulmonary 
hypertension and RV failure in the perioperative period are 
common (1.78%) complications of cardiopulmonary bypass 
circulation during open-heart operations (Ocal et al 2005).
Pulmonary hypertension can also develop later as a result 
of ARDS (Milot et al 2001) or other complications (sepsis, 
PE, etc) not directly related to either surgery or anesthesia.
Diagnosis and monitoring 
of patients with pulmonary 
hypertension in ICU
A high level of suspicion is the key point in establishing a 
timely diagnosis of acute arterial pulmonary hypertension. 
Clinical presentation, physical exam, electrocardiogram 
and chest radiography can suggest pulmonary circulation 
abnormality. However, those data are not speciﬁ  c enough 
to be useful in diagnosing acute pulmonary hypertension in 
ICU. Pulmonary hypertension is usually recognized when 
the patient develops obvious signs of progressive RV failure, 
and during hemodynamic monitoring by echocardiogram or 
a pulmonary artery catheterization. In many cases pulmonary 
hypertension remains undiagnosed and its treatment begins 
only after serious complications have developed. Timely Vascular Health and Risk Management 2008:4(5) 1048
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assessment of pulmonary artery pressures, cardiac output 
(CO) and pulmonary vascular resistance with the help of 
pulmonary artery catheterization and/or echocardiography is 
crucial for optimal management of patients with pulmonary 
hypertension. The role of alternative diagnostic tests such 
as volumetric capnography is unclear at present (Moreira 
et al 2007).
Pulmonary artery catheterization
Pulmonary artery (PA) catheterization is considered a 
gold standard for the diagnosis of pulmonary hypertension 
(Chemla et al 2002) when chronic pulmonary hypertension 
is suspected. Besides direct measurement of the pulmonary 
hemodynamic parameters it also provides useful information 
regarding response to vasodilator therapy. Analysis of 
mixed venous oxygen saturations during passage of the 
PA catheter on its way through the cardiac chambers 
can allow diagnosis of intracardiac shunts. A pulmonary 
capillary wedge pressure (PCWP) measurement reﬂ  ects left 
ventricular end-diastolic (ﬁ  lling) pressure. Values  15 mm 
Hg rule out left ventricular, valvular and pulmonary venous 
diseases as possible causes of the pulmonary hypertension 
(Chemla et al 2002).
In critical care settings PA catheterization and monitoring 
is highly desirable in patients with severe pulmonary 
hypertension and in patients with progressive heart failure 
(Fincke et al 2004). It is important to emphasize that 
the thresholds required for diagnosis of severe chronic 
pulmonary hypertension are incompatible with life in 
patients with acute pulmonary hypertension and usually 
reﬂ  ect worsening of preexisting chronic pulmonary hyper-
tension. Although there is a little doubt that hemodynamic 
data are valuable in the care of critically ill patients with 
acute conditions complicated by pulmonary hypertension, 
there is no data available on how PA monitoring could affect 
management and outcome of these patients. Indeed, placing a 
PA catheter could be a challenging and dangerous procedure 
in such patient population. Technical difﬁ  culties could be 
related to severe tricuspid regurgitation, RV dilatation, 
elevated PAP, and decreased cardiac output. Complications 
of PA catheterization are particularly dangerous in patients 
with pulmonary hypertension and RV dysfunction/failure. 
Arrhythmias in response to PA catheterization can have 
potentially life-threatening consequences by decreasing 
cardiac output, or induction of fatal ventricular arrhythmias. 
Obtaining a PCWP may be technically difﬁ  cult in patients 
with markedly elevated PAP, and also carries a high risk 
of sometimes fatal pulmonary arterial rupture. Finally, the 
presence of tricuspid regurgitation can signiﬁ  cantly decrease 
the accuracy of cardiac output calculations by thermodilution. 
Theoretically, Fick’s method could be more accurate, but in 
critically ill patients with increased pulmonary metabolism 
and high or very low cardiac output its accuracy may not be 
optimal (Caruso et al 2002).
Echocardiography
Echocardiography has become an important tool not only 
for screening of chronic pulmonary hypertension, but also 
for diagnosing and determining the degree and clinical 
signiﬁ  cance of pulmonary hypertension in critically ill 
patients (Hoeper et al 2002; Humbert et al 2004). It can 
noninvasively visualize cardiac anatomy and certain 
intracardiac shunts and valvular abnormalities, estimate 
right atrial and PAP, determine the severity of right and 
left ventricular dysfunction, wall motion abnormalities and 
reveal other potential causes of pulmonary hypertension. In 
the absence of pulmonary outﬂ  ow obstruction, pulmonary 
artery systolic pressure is equivalent to right ventricular 
systolic pressure (RVSP), which can be calculated from 
measured systolic regurgitant tricuspid ﬂ  ow velocity and 
estimated right atrial pressure. Pulmonary hypertension is 
usually deﬁ  ned as RVSP  35 mm Hg with the expected 
upper normal limit up to 40 mm Hg in older or obese subjects 
(McQuillan et al 2001). Among 3790 healthy people who 
underwent echocardiography RVSP was highly variable 
in the range of 15–57 mmHg and was associated with 
age, body mass index (BMI), gender, wall thickness, and 
ejection fraction. A RVSP  40 mm Hg was found in 6% of 
those  50 years old and 5% of those with a BMI  30 kg/m2 
(McQuillan et al 2001). Therefore, not every elevation of 
RVSP indicates a presence a pathological condition. Possible 
explanations for mildly elevated RVSP detected by echo-
cardiography include (Barst et al 2004): 1) overestimation 
of the RVSP in a patient with true normal pulmonary pres-
sure; 2) serendipitous observation of a transient pressure 
elevation in an otherwise healthy individual; 3) discovery 
of stable mild pulmonary hypertension; or 4) discovery of 
early progressive PAH.
Echocardiographic signs of significant pulmonary 
hypertension include RV dilation (D-shaped right ventricle) 
and its hypertrophy (in sustained cases), septal dyskinesia and 
bowing into the LV during late systole to early diastole, RV 
hypokinesis, tricuspid regurgitation, right atrial enlargement, 
and a dilated inferior vena cava (Chemla et al 2002; 
Vieillard-Baron et al 2002; Bossone et al 2005). In patients 
with chronic PAH predictors of poor outcome include right Vascular Health and Risk Management 2008:4(5) 1049
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atrial enlargement, septal bowing, and the development of a 
pericardial effusion (Raymond et al 2002).
Increased RV size combined with increased outﬂ  ow 
resistance and reduced ejection fraction have been also 
described in acute cor pulmonale (Vieillard-Baron et al 2002). 
A speciﬁ  c pattern of RV dysfunction in acute pulmonary 
embolism has been characterized by a severe hypokinesia of 
the RV mid-free wall, with normal contractions of the apical 
segment (McConnell et al 1996).
TTE results were poorly predictive of the risk of death in 
patients who developed acute cor pulmonale (Lambermont 
et al 2003). However, deﬁ  nition of the acute cor pulmonale 
as right ventricular end-diastolic area/left ventricular 
end-diastolic area (RVEDA/LVEDA) ratio in the long axis 
greater than 0.6 associated with septal dyskinesia in the short 
axis could be used to stratify the severity of the condition 
(Vieillard-Baron et al 2001a; Engelke et al 2006).
Images may be suboptimal in critically ill patients 
because of limitations related to patient’s general condition, 
limited positioning, attached monitoring devices, wound 
dressings, or ventilatory support. TEE may be more 
accurate and sensitive in critically ill patients than TTE, 
especially in acute diseases such as pulmonary embolism 
when acute pulmonary hypertension is highly suspected 
(Karski 2006). Newly developed handheld ultrasound 
devices capable of TEE may sufﬁ  ciently replace a standard 
cart-based TEE system in unstable critically ill patients 
(Schneider et al 2007).
Advanced Doppler ECHO techniques allow for 
comprehensive hemodynamic assessment of the patients 
with pulmonary hypertension. A high correlation between 
PA catheter and Doppler echocardiography evaluations of 
cardiac output, transpulmonary gradient and PVR were 
observed in patients with severe pulmonary hypertension 
(Selimovic et al 2007).
Troponin
Serum troponin may be elevated in patients with pulmonary 
hypertension and has been associated with RV overdisten-
sion and/or ischemia. Troponin I leak due to acute right 
ventricular strain from pulmonary embolism has been well 
studied, and may predict mortality (Mehta et al 2003; La 
Vecchia et al 2004).
Natriuratic peptides
Elevated BNP is an important prognostic indicator and 
correlates strongly with PVR, cardiac output, and func-
tional status in patients with PAH (Leuchte et al 2004). 
A high level of plasma BNP, and in particular, a further 
increase in plasma BNP during follow-up, may have a 
strong, independent association with increased mortality 
rates in this patient population (Nagaya et al 2000). How-
ever, the signiﬁ  cance of measuring BNP level in patients 
with pulmonary hypertension in the acute setting remains 
unclear.
Management of arterial pulmonary 
hypertension in noncardiac ICU
General management principles
Acute on chronic pulmonary hypertension
Patients with chronic pulmonary hypertension usually have 
multiple predisposing factors (Table 3), which make them 
more vulnerable to acute conditions and explain decreased 
ability to survive acute illness (Hoeper et al 2002). Tighter 
monitoring combined with early diagnosis and appropriate 
intervention increases the chance of survival. Treatment strat-
egies for such patients should be generally directed at rapid 
reversal of the precipitating condition as well as at relieving 
RV pressure overload and maintaining systemic pressure 
for coronary and end organ perfusion. Unlike patients with 
acute pulmonary hypertension (Chin et al 2005), patients who 
develop acute pulmonary hypertension on top of preexisting 
pulmonary hypertension can generate higher pulmonary 
arterial pressure and also require higher RV preload (because 
of RV hypertrophy).
Massive pulmonary embolism
Therapy for acute massive pulmonary embolism with 
associated hemodynamic instability or cardiogenic/obstructive 
shock aims at urgently relieving mechanical obstruction of the 
pulmonary circulation by either pharmacologic thrombolysis 
or by surgical or catheter thrombectomy (or mechanical clot 
disruption) (Buller et al 2004; Yoshida et al 2006). Patients 
with massive PE but without hemodynamic instability 
are less likely to beneﬁ  t from thrombolytic therapy. The 
time the resolution of RV dilatation, which usually takes 
between 10 and 20 days, is hastened by thrombolytic therapy 
(Vieillard-Baron et al 2001a).
Pulmonary hypertension associated 
with ARDS and sepsis
The therapy of acute pulmonary hypertension in patients 
with sepsis and ARDS is generally aimed at optimizing gas 
exchange and minimizing ventilator induced lung injury. 
Inhaled pulmonary vasodilators are sometimes used in order 
to prevent or relieve acute cor pulmonale.Vascular Health and Risk Management 2008:4(5) 1050
Tsapenko et al
Pulmonary vasodilators
Ability to produce sustained pulmonary vasodilation is not 
the only factor affecting the decision to choose particular 
vasodilator in treatment of acute pulmonary hypertension. 
Route of administration, half-life and systemic effects should 
also be considered. Vasodilators administered intravenously 
may decrease PVR, but they also have longer half lives and 
affect systemic circulation. A decrease in systemic mean 
arterial pressure may result in reduced right coronary blood 
ﬂ  ow and further deterioration of RV performance. Inhalation 
of pulmonary vasodilators can improve ventilation/perfusion 
(V/Q) matching by reaching and subsequently vasodilating 
only well ventilated areas of the lung. Inhaled pulmonary 
vasodilators with a short half-life and no systemic vasodila-
tion effect are considered a treatment of choice for acute 
arterial pulmonary hypertension.
Inhaled NO
Inhaled NO (INO) is a potent vasodilator that dilates pulmo-
nary vasculature in ventilated lung areas, thereby improving 
V/Q match and oxygenation, and reducing PAP (Pepke-Zaba 
et al 1991) and RV oxygen demand (Zwissler et al 1995). 
This improves cardiac performance without altering RV 
contractility (Cockrill et al 2001) and cardiac output in 
hemodynamically stable patients with a variety of causes of 
pulmonary hypertension (Fierobe et al 1995; Bhorade et al 
1999). INO has a very short half-life and almost no systemic 
vasodilatory effects, which is very important in treatment of 
hemodynamically unstable patients. While underlying causes 
of RV failure and baseline hemodynamics did not predict 
response to INO, the use of alpha-agonist catecholamines 
did (Bhorade et al 1999).
Multiple studies on utilization of the INO in ARDS 
patients showed improved oxygenation for 24–48 hours, 
variable improvement in mean PAP (McIntyre et al 1995) 
and no signiﬁ  cant impact on the duration of ventilatory 
support or mortality in this patient population (Kaisers et al 
2003; Taylor et al 2004). A combination of INO and other 
interventions, such as positive end-expiratory pressure and 
prone positioning, yielded beneﬁ  cial and additive effects 
on arterial oxygenation (Kaisers et al 2003). INO has been 
successfully used and associated with improved outcomes 
in critically ill postoperative patients, who developed severe 
pulmonary hypertension or RV failure (Della Rocca and 
Coccia 2005; George et al 2006).
A combination treatment of INO with other pulmonary 
vasodilators (milrinone, sildenaﬁ  l etc) has been used in 
management of acute pulmonary hypertension in different 
conditions (Deb et al 2000; Lepore et al 2005b). INO 
treatment is associated with multiple side effects including 
methemoglobinemia (Pepke-Zaba et al 1991; Troncy et al 
1997) and NO2 formation (Troncy et al 1997). Abrupt with-
drawal of NO has been associated with rebound pulmonary 
hypertension, signiﬁ  cant drop in PaO2 and life-threatening 
hemodynamic deterioration (Troncy et al 1997; Christenson 
et al 2000). Close monitoring and gradual discontinuation 
is important to prevent and detect rebound pulmonary 
hypertension.
Prostaglandins
Prostaglandin E1 and prostacyclin both produce signiﬁ  cant 
pulmonary vasodilatation and can lower PVR. Both pos-
sess antithrombotic, antiproliferative and anti-inﬂ  ammatory 
properties. In patients with chronic severe pulmonary hyper-
tension, intravenous prostacyclin is highly effective and 
associated with a signiﬁ  cant survival beneﬁ  t (McLaughlin 
et al 1998, 2002). Prostacyclin, subcutaneous or intravenous 
treprostinil, intravenous PGE1 and other prostanoids have 
relatively long half-lives and can signiﬁ  cantly affect systemic 
hemodynamics. This feature limits their use in critically ill or 
hemodynamically unstable patients. Intravenous prostacyclin 
(PGI2) in combination with norepinephrine and dopamine 
was effective in the treatment of protamine-mediated acute 
pulmonary hypertension and RV failure in the setting of open 
heart surgery (Ocal et al 2005).
Prostacyclin and its analogs (iloprost and treprostinil) 
in inhaled forms are as effective as intravenous forms in 
patients with chronic pulmonary hypertension (Gomberg-
Maitland and Olschewski 2008). In the ICU setting inhaled 
prosaglandins have been used to treat severe sustained 
pulmonary hypertension and intractable hypoxia, but were 
associated with systemic hypotension (Hache et al 2001). 
Inhaled iloprost effectively decreased pulmonary artery 
pressure and improved RV performance immediately after 
separation from cardiopulmonary bypass (Theodoraki et al 
2002). Inhaled iloprost was effective in the treatment of acute 
RV dysfunction in the setting of pre-existing pulmonary 
hypertension in heart transplant recipients during weaning 
from cardiopulmonary bypass circulation and was not associ-
ated with signiﬁ  cant systemic side-effects.
Despite the observation that RV ejection fraction increased 
on INO, but not with PGI2, both INO and PGI2-aerosol showed 
beneﬁ  cial effects on RV performance and may prove helpful 
in the treatment of acute pulmonary hypertension (Zwissler 
et al 1995). Inhaled prostacyclin showed different effect 
on oxygenation and pulmonary hemodynamics in patients Vascular Health and Risk Management 2008:4(5) 1051
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presenting with primary pulmonary ARDS (reduction in 
PaO2/FIO2) compared with extrapulmonary cause of ARDS 
(increase in PaO2/FIO2 along with a decrease in mean PAP) 
(Domenighetti et al 2001).
Milrinone
Milrinone is a selective phosphodiesterase-3 inhibitor with 
signiﬁ  cant inotropic and vasodilatory effects for both pulmo-
nary and systemic vasculatures. It is widely used alone or in 
combinations in patients with decompensated heart failure, 
particularly in those with nonischemic left ventricular systolic 
dysfunction (Mehra et al 1997; elker et al 2003) and cardiac 
surgery patients (Levy et al 2002; Lee et al 2006). In animal 
models of both acute and chronic pulmonary hypertension, 
milrinone signiﬁ  cantly reduced PVR and improved RV 
function (Chen et al 1997; Hashiba et al 2000). In cardiac 
surgery patients with a history of pulmonary hypertension, 
INO was associated with lower heart rates, higher right 
ventricular ejection fraction, and a lower requirement for 
treatment with vasopressor agents compared to milrinone 
(Solina et al 2000).
The systemic vasodilatory effect of milrinone along with 
relatively long half life is the major limiting factors against 
its utilization in conditions associated with systemic hypoten-
sion or hemodynamic instability. However, in combination 
with INO, milrinone produced additive pulmonary vasodi-
latation in animal model of acute pulmonary hypertension 
(Deb et al 2000). A combination of milrinone and sildenaﬁ  l 
led to more effective pulmonary vasodilation and increased 
RV contractility, without additional systemic vasodilatation 
in an animal model. CO and RV performance were sig-
niﬁ  cantly improved after milrinone or both drugs combined, 
but not with sildenaﬁ  l alone (Lobato et al 2006). Systemic 
vasopressors, both norepinephrine and low dose vasopressin 
were effective in the treatment of milrinone-induced systemic 
hypotension. However, milrinone-vasopressin combination 
was associated with better hemodynamics than milrinone-
norepinephrine during the management of right heart 
failure (Jeon et al 2006). In a volume-resuscitated pediatric 
patient with septic shock, when administered in addition to 
catecholamines, milrinone improved cardiovascular function 
(Barton et al 1996).
In an animal model of drug-induced pulmonary hyper-
tension nebulization of milrinone failed to deliver sufﬁ  cient 
amount of milrinone for producing a detectable hemodynamic 
effect (Gelvez et al 2004), but in animals with induced CHF 
inhalation of milrinone predominantly dilated pulmonary 
blood vessels, resulting in a reduced pulmonary-to-systemic 
vascular resistance ratio and improvement of pulmonary 
venous hypertension (Hentschel et al 2007). At the same 
time, in animals after cardiopulmonary bypass inhaled 
milrinone produced adequate hemodynamic and oxygenation 
proﬁ  les, and prevented the occurrence of the pulmonary 
endothelial dysfunction. (Lamarche et al 2005).
Sildenaﬁ  l and other phosphodiesterase-5 inhibitors
Sildenaﬁ  l is a speciﬁ  c phosphodiesterase-5 inhibitor with 
sustained pulmonary vasodilatatory effect. Sildenaﬁ  l lowers 
PVR, PAP, and increases CO in patients with different 
forms of chronic pulmonary hypertension (Michelakis et al 
2002; Mikhail et al 2004) including patients with pulmonary 
hypertension secondary to congestive heart failure (Lepore 
et al 2005b). This effect is mainly achieved by balancing 
pulmonary and systemic vasodilation. In patients after 
coronary artery bypass graft surgery sildenaﬁ  l may improve 
myocardial perfusion, reduce platelet activation, and poten-
tially reduce early graft occlusion (Fung et al 2005). In the 
chronic setting it is highly effective both alone and in com-
bination with other pulmonary vasodilators: epoprostenol 
(Stiebellehner et al 2003), iloprost (Ghofrani et al 2002, 
2003), brain natriuretic peptide (BNP) (Klinger et al 2006), 
and inhaled NO (Lepore et al 2005b). Although mostly used 
in patients with chronic pulmonary hypertension and in 
hemodynamically stable patients sildenaﬁ  l possesses multiple 
features that could be effective in treatment of critically ill 
patients with severe RV dysfunction related to secondary pul-
monary hypertension (Ng et al 2005). Its ability to augment 
and prolong the hemodynamic effects of other pulmonary 
vasodilators has been successfully used to minimize rebound 
pulmonary hypertension after INO discontinuation (Atz and 
Wessel 1999; Trachte et al 2005; Namachivayam et al 2006), 
weaning from intravenous vasodilators in patients after 
cardiac surgery (Trachte et al 2005) as well as in chronic 
PAH therapy (Johnson et al 2007).
Experimental evaluation of the inhaled and intravenous 
sildenaﬁ  l administration showed similar effects on pulmo-
nary endothelium-dependent relaxation, overall hemody-
namic proﬁ  le and oxygenation after cardiopulmonary bypass. 
Both administration routes prevented a signiﬁ  cant increase 
in mean PAP without severe systemic hypotension (Aubin 
et al 2008).
Two other speciﬁ  c phosphodiesterase-5 inhibitors: zapri-
nars and dipyridamole seem to be potentially very effective 
in the management of acute pulmonary hypertension. Admin-
istration of either of these drugs leads to dose-dependent 
pulmonary vasodilation and no signiﬁ  cant systemic arterial Vascular Health and Risk Management 2008:4(5) 1052
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hypotension (Matot and Gozal 2004). Intravenous zaprinast 
may increase the efﬁ  cacy and prolong the duration of action 
of INO. However, its efﬁ  cacy in lung injury models was 
uncertain: nonselective vasodilation induced by intravenously 
administered zaprinast not only worsens gas exchange, but 
also abolishes the beneﬁ  cial effects of INO (Adrie et al 2000). 
Subthreshold doses (which do not reduce PAP) of speciﬁ  c 
phosphodiesterase-5 inhibitors (zaprinast and sildenaﬁ  l) 
when used in acute lung injury (ALI) associated with pul-
monary hypertension improved responsiveness to NO (Klein 
et al 2007). Dipyridamole effectively slows the progression of 
hypoxemic pulmonary hypertension in patients with COPD 
(Nenci et al 1988). In an animal model of acute pulmonary 
hypertension, IV dipyridamole in combination with INO 
decreased pulmonary artery pressure for a prolonged period 
of time and reduced exposure to NO (Foubert et al 2003). 
Dipyridamole can lower PVR, augment INO-induced pulmo-
nary vasodilation, acutely attenuate the adverse hemodynamic 
effects of rapid withdrawal of INO therapy (Ivy et al 1998), 
and attenuate excessive hypoxic pulmonary vasoreactivity 
(Ziegler et al 1998). In pediatric patients with pulmonary 
hypertension dipyridamole decreased PVR index to similar 
values as INO did, but with signiﬁ  cant systemic vasodilata-
tion (Ziegler et al 1998). Intravenous dipyridamole has been 
used to identify reversibility of pulmonary hypertension in 
potential cardiac transplant recipients with CHF in whom a 
pulmonary vasodilator response to inhalation of NO alone 
is not observed (Lepore et al 2005a). Intravenous dipyri-
damole was also used in acute management of pulmonary 
hypertension in combination either with INO or intravenous 
nitroglycerin (Sulica et al 2005).
Natriuretic peptides
Natriuretic peptides (atrial natriuretic peptide [ANP] and 
brain natriuretic peptide [BNP]) in addition to their diuretic, 
vasorelaxing, and hemodynamic effects are able to inhibit 
vascular smooth-muscle proliferation and cardiac hyper-
trophy, as well as counteract the renin–angiotensin system 
(Krupicka et al 2008). ANP and BNP produced dose-related 
pulmonary vasodilatation in patients with cor pulmonale, 
without worsening oxygen saturation or affecting systemic 
hemodynamics and exerted favorable neurohormonal effects 
by suppressing aldosterone (Cargill and Lipworth 1996). 
Although both ANP and BNP exhibit pulmonary vasorelax-
ing activity, only BNP signiﬁ  cantly attenuated the mean PAP 
and acute hypoxic pulmonary vasoconstriction in otherwise 
healthy individuals (Cargill and Lipworth 1995). BNP alone 
had no effect on mean PAP or PVR in patients with PAH, 
but was well tolerated and augmented the acute pulmonary 
vasodilator effect of sildenaﬁ  l (Klinger et al 2006). Nesiritide 
acutely and signiﬁ  cantly reduced PA pressure, PVR, and 
biventricular ﬁ  lling pressures in patients with postcapil-
lary pulmonary hypertension. However, in patients with 
precapillary pulmonary hypertension, it had no signiﬁ  cant 
acute hemodynamic effect on the pulmonary hemodynamics 
(Michaels et al 2005). Use of nesiritide in hemodynamically 
unstable and hypotensive patients is limited, mainly because 
of reduction of systemic vascular resistance and resulting 
profound systemic hypotension (Yancy et al 2007).
Other pulmonary vasodilators
Nitroprusside and nitroglycerin both can cause signiﬁ  cant 
pulmonary vasodilation similar to that of INO. However, 
nitroprusside has a longer half life and can cause acute 
reduction of systemic vascular resistance leading to systemic 
hypotension associated with a decrease in RV contractility, 
limiting its use in hemodynamically unstable and hypotensive 
patients (Cockrill et al 2001). A signiﬁ  cant venodilator effect 
of nitroglycerine decreases RV preload leading to adverse 
consequences in patients with right heart failure. Inhaled 
nitroglycerin may be a safer therapeutic option leading to a 
signiﬁ  cant reduction in both mean PAP and PVR in patients 
after mitral valve operations without reducing systemic mean 
arterial pressure (Yurtseven et al 2003).
Intravenous adenosine is a pulmonary vasodilator with a 
very short half-life (6–10 sec.) and can be effective for short 
term lowering PVR (McLaughlin et al 1998). In the setting of 
acute pulmonary hypertension adenosine infusion may help 
lower PAP without lowering systemic arterial pressure and 
reverse the clinical state of shock by achieving pulmonary 
vasodilatation (Fullerton et al 1996). However, higher doses 
(70 mg/kg per min to 100 mg/kg per min) cause systemic 
vasodilation (Stobierska-Dzierzek et al 2001). Adenosine 
is used to treat persistent pulmonary hypertension of the 
newborn (Ng et al 2004; Motti et al 2006).
Calcium channel blockers have been used in hemodynam-
ically stable patients with PAH who demonstrated pulmonary 
vascular response to acute vasodilator challenge (Badesch 
et al 2007). There are no studies of calcium channel blockers 
in critically ill patients with acute pulmonary hypertension. 
Acute administration of nifedipine did not cause pulmonary 
vasodilation, and in contrast led to increased RVEDP and 
decreased RV contractility (Cockrill et al 2001). Prolonged 
half-life and negative inotropic effects, which may precipitate 
fatal worsening of RV failure, limit the use of calcium chan-
nel blockers in treatment of acute pulmonary hypertension.Vascular Health and Risk Management 2008:4(5) 1053
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Endothelin receptor antagonists appear to be highly 
effective in treatment PAH in outpatient settings (Badesch 
et al 2007). They have not been studied in acute care settings. 
In an animal model pre-treatment with bosentan completely 
abolished endotoxin-induced acute pulmonary hyperten-
sion and changes in pulmonary compliance and resistance 
(Albertini et al 2001). Currently the only possible implica-
tion in critically ill patients would be weaning or conversion 
from inhaled or intravenous pulmonary vasodilators to oral 
medication (bosentan) (Johnson et al 2007).
Vasopressors and inotropic agents
Critically ill patients with associated acute pulmonary 
hypertension frequently develop profound and refrac-
tory systemic arterial hypotension. In cases with severe 
acute arterial pulmonary hypertension (eg, massive PE) 
relieving the acute obstruction (either mechanically or with 
pulmonary vasodilators) of the pulmonary circulation can 
successfully resolve systemic arterial hypotension. In acute 
pulmonary hypertension associated with decreased cardiac 
contractility and/or systemic vascular resistance (SVR) the 
use of vasopressors with or without pulmonary vasodilators 
is necessary to maintain coronary and end organ perfusion. 
Progression of RV failure should be always considered in 
the management plan. Cases of severe acute pulmonary 
hypertension combined with heart failure and systemic 
arterial hypotension require tight hemodynamic monitoring 
and aggressive treatment with combinations of pulmonary 
vasodilators, inotropic agents and systemic arterial vaso-
constrictors. The choice of vasopressor and inotropes in 
patients with acute pulmonary hypertension should take into 
consideration their effects on PVR and cardiac output when 
used alone or in combinations with other agents, and must 
be individualized based on individual patient response. Most 
traditional vasopressors and inotropes have not been studied 
in the setting of severe acute arterial pulmonary hypertension 
and hemodynamic instability.
Dobutamine is the most studied inotropic agent in 
patients with pulmonary hypertension. Administration of 
dobutamine augments myocardial contractility and reduces 
left ventricular afterload. It can cause systemic hypotension 
in some patients because of peripheral vasodilatory effects, 
which may require use of norepinephrine or other peripheral 
vasoconstrictors to maintain appropriate systemic perfusion 
pressures. In low doses (up to 5 μg/kg/min) dobutamine 
decreased PVR, lowered MAP and slightly increased cardiac 
output (Bradford et al 2000); at doses of 5–10 μg/kg per min, 
dobutamine caused signiﬁ  cant tachycardia and systemic 
hypotension without improving PVR (Bradford et al 2000; 
Kerbaul et al 2004). In combination with INO dobutamine 
administration had additive effects on pulmonary circulation 
(Bradford et al 2000), increased cardiac performance and 
improved oxygenation (P/F patio) (Vizza et al 2001) with 
no effect on systemic hemodynamics. In an animal model of 
acute RV failure secondary to acute pulmonary hypertension, 
dobutamine was superior to norepinephrine in improving RV 
function by optimizing pulmonary vasodilation, decreasing 
PA resistance and elastance and increasing RV contractility 
(Kerbaul et al 2004).
Norepinephrine has signiﬁ  cant inotropic effects and 
produces vasoconstriction. It is widely used in critical care 
settings to treat hemodynamically unstable patients. In 
addition to positive effects on cardiac output and systemic 
arterial pressure, norepinephrine increases PVR and worsens 
pulmonary artery hypertension (Kwak et al 2002). However, 
norepeinephrine is superior to phenylephrine in restoring 
systemic arterial pressure, decreasing PVR, augmenting right 
ventricular myocardial blood ﬂ  ow and improving cardiac 
output in animal model of acute PE (Hirsch et al 1991). 
Alfa-adrenergic stimulation can cause a disproportionate 
rise in PVR (Brimioulle et al 1997) which is implicated 
in the development of acute pulmonary hypertension in 
critical illnesses. Besides disproportional a increase in PVR 
phenylephrine also causes bradycardia (Tisdale et al 1995) 
with detrimental consequences on pulmonary and systemic 
hemodynamic.
The effects of phenylephrine and norepinephrine in the 
treatment of systemic hypotension were evaluated in patients 
with chronic pulmonary hypertension who developed sys-
temic hypotension following induction of anesthesia. In 
contrast to phenylephrine norepinephrine decreased the ratio 
of pulmonary arterial pressure to systemic blood pressure 
without a change in cardiac index. Thus, norepinephrine has 
been considered to be preferable to phenylephrine for the 
treatment of hypotension in patients with chronic pulmonary 
hypertension (Kwak et al 2002). There is growing data (as we 
have partially presented earlier) on successful combination 
of norepinephrine and selective pulmonary vasodilators in 
the treatment of patients with acute and chronic pulmonary 
hypertension (Tritapepe et al 1999).
Dopamine produces dose dependent dopaminergic, beta- 
and alpha-adrenergic effects on cardiac output and vascular 
tone. In patients with chronic pulmonary hypertension dopa-
mine infusion led to increased heart rate, mean PAP, aortic mean 
pressure, and cardiac index with concomitant fall of systemic 
vascular resistance (Holloway et al 1975). Administration Vascular Health and Risk Management 2008:4(5) 1054
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of dopamine, similar to epinephrine, is associated with high 
risk of tachyarrhythmia, with potentially fatal consequences 
in patients with severe pulmonary hypertension (Tisdale et al 
1995). In a small animal study of sepsis-induced pulmonary 
hypertension epinephrine infusion increased SVR and cardiac 
output and lowered PVR (Meadow et al 1986). There is no 
other supportive data on use epinephrine in patients with 
chronic or acute pulmonary hypertension.
Isoproterenol has positive inotropic and chronotropic 
effect, which in therapeutic doses increases cardiac output 
and produces pulmonary and peripheral vasodilation. As a 
pulmonary vasodilator, isoproterenol is one of the preferred 
inotropic agents in heart transplantation patients with elevated 
PVR. The dosage of isoproterenol should be reduced gradu-
ally because PVR may return quickly to elevated baseline 
levels after discontinuation of this drug (Stobierska-Dzierzek 
et al 2001). In animals with acute pulmonary hypertension 
administration of isoproterenol did not reduce PAP, and 
instead produced signiﬁ  cant tachycardia and was associated 
with arrhythmias (Prielipp et al 1991).
Vasopressin is an endogenous hormone with weak non-
adrenergic vasopressor effect on the systemic vasculature 
and an ability to produce NO mediated selective pulmonary 
vasodilation (Evora et al 1993). In healthy animals a linear 
relationship was observed between vasopressin levels and 
systemic vascular resistance. However, vasopressin did not 
affect PVR or any vascular compliance (Wallace et al 1989). 
It was very effective (at dose of 0.1 U/min) in treating refrac-
tory low SVR hypotension concomitant with pulmonary 
hypertension in postoperative patients (Tayama et al 2007). 
Experimental data on use of vasopressin in acute pulmonary 
hypertension is controversial: In one setting of acute pulmo-
nary vasoconstriction vasopressin infusion produced signiﬁ  -
cant pulmonary vasodilation (Trempy et al 1994). Use of high 
dose of vasopressin (1.16 units/kg/h ) in another animal model 
of acute pulmonary hypertension led to increased PVR and 
decreased cardiac output with a decrease in RV contractility, 
leading the authors to cautioning against its use when RV 
function is compromised (Leather et al 2002) .
Experimental data suggest that levosimendan (a myocar-
dial and vascular calcium sensitizer) has pulmonary vaso-
dilatory properties which, in combination with its positive 
inotropic effects, would render it particularly attractive for 
the treatment of RV dysfunction related to acute pulmonary 
hypertension. In a model of acute right ventricular dysfunc-
tion, levosimendan improved global hemodynamics and 
optimized right ventriculo-vascular coupling via a moder-
ate increase in RV contractility and a mild reduction of RV 
afterload (Missant et al 2007). A similar effect was achieved 
in an animal model of progressive pulmonary hypertension 
and RV failure related to recurrent pulmonary embolism 
(Kerbaul et al 2007). In those settings levosimendan restored 
RV function better than dobutamine because of similar 
inotropic effects and additional pulmonary vasodilatory 
effects (Kerbaul et al 2004) Levosimendan was successfully 
combined with milrinone in one study (Stocker et al 2007). 
A pilot prospective, randomized study on patients with ARDS 
in association with septic shock showed that levosimendan 
improves right ventricular performance mainly through 
pulmonary vasodilator effects (Morelli et al 2006).
Fluid management
Experiments in 1983 showed that when RV afterload is 
increased, even a relatively small increase in preload may 
result in RV dysfunction. RV dysfunction occurred with 
volume expansion, despite constant PVR and a decrease in 
mean PAP. This and further observations draw the conclusion 
that high RV ﬁ  lling pressure restores normal hemodynamics 
only if PVR is normal and RV contractility is not markedly 
reduced (Via and Braschi, 2004).
In patients with pulmonary hypertension, RV dysfunc-
tion/failure can reduce LV ﬁ  lling and lead to cardiogenic 
shock. Patients with cardiogenic shock secondary to RV dys-
function usually have a very high ( 20 mm Hg) RV ﬁ  lling 
pressure (Jacobs et al 2003). In addition to decreased RV 
contractility and cardiac output RV dilatation can further 
limit LV ﬁ  lling via ventricular interdependence, which causes 
shifting of the interventricular septum toward the LV cavity. 
Following the traditional paradigm that RV failure is treated 
with aggressive ﬂ  uid resuscitation can, thus, worsen the 
patient’s condition. The challenge in ﬂ  uid management in 
those patients is to ﬁ  nd the optimal RV preload necessary to 
avoid the detrimental effects of ventricular interdependence 
on LV function. Hemodynamic monitoring of patients with 
RV failure due to acute RV myocardial infarction showed that 
cardiac and stroke indexes increased and the RV reached its 
maximum stroke work index when the ﬁ  lling pressure was 
10–14 mm Hg. These values may be regarded as the optimal 
level of RV ﬁ  lling pressure in patients with RV infarction 
(Berisha et al 1990). There is no data on optimal RV ﬁ  lling 
pressure in patients with RV dysfunction secondary to acute 
pulmonary hypertension.
Ventilator management
It was found that controlled ventilation altered RV func-
tion primarily by increasing RV afterload during the lung Vascular Health and Risk Management 2008:4(5) 1055
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inﬂ  ation period (Jardin et al 1990). Transpulmonary pressure 
(and related tidal volume), but not airway pressure itself, 
was the main determinant factor of RV afterload during 
mechanical ventilation (Vieillard-Baron et al 1999). This 
supports a low-volume strategy in ARDS, recommended as 
a protective measure for lung parenchyma, which might also 
represent a protective measure for the RV and pulmonary 
circulation (Vieillard-Baron et al 1999). Frequency of acute 
cor pulmonale in ARDS patients declined from 61% to 25% 
over the last 15–30 years, which could be explained in part 
by fundamental alterations in respiratory support and imple-
mentation low tidal volume ventilation (Vieillard-Baron et al 
2001b). Lower incidence of acute cor pulmonale in ARDS 
patients was associated with lower (less then 27–30 mmHg) 
plateau pressure (Jardin and Vieillard-Baron 2007).
RV systolic function was generally negatively affected by 
end-expiratory pressure (PEEP) in ARDS patients undergo-
ing mechanical ventilation. In those patients PEEP titration 
signiﬁ  cantly affected RV outﬂ  ow impedance, the lowest 
values of which was associated with the achieved better total 
quasi-static lung compliance (calculated by dividing tidal 
volume by the difference between plateau and end-expiratory 
airway pressures) (Schmitt et al 2001). This suggests that 
lung hyperinﬂ  ation along with either inadequate or exces-
sive PEEP can signiﬁ  cantly reduce RV systolic function and 
cardiac output. On other hand, in an experimental study on 
healthy animals, the open lung concept ventilation resulted in 
signiﬁ  cantly improved lung aeration with no negative effect 
on RV afterload or LV afterload. This is possibly explained 
by a loss of hypoxic pulmonary vasoconstriction due to alveo-
lar recruitment. The reductions in the CO and in the mean 
PAP were the consequences of a reduced preload (Miranda 
et al 2006). A clinical study in patients after cardiac surgery 
found no evidence that ventilation according to the open lung 
concept affects RV afterload (Reis Miranda et al 2004).
Hypercapnia has been shown to induce pulmonary hyper-
tension in animal models. There is no data on how it could 
affect acute pulmonary hypertension in humans. However, 
study on healthy volunteers revealed that human pulmonary 
vascular responses to hypercapnia and hypocapnia consist, 
respectively, of constriction and dilatation that take 1.5–2 h to 
reach a steady level. The time courses for recovery in eucap-
nia are similar. Hypercapnia generated a rise in cardiac output 
by changing heart rate; hypocapnia produced a fall in cardiac 
output by changing stroke volume. The ﬁ  nding of marked 
vasodilatation in response to hypocapnia demonstrates that 
there is normally a substantial vascular tone in the human 
pulmonary circulation (Balanos et al 2003).
Treatment with 100% oxygen is a selective pulmonary 
vasodilator in patients with sustained pulmonary hyperten-
sion, regardless of primary diagnosis, baseline oxygenation, 
or right ventricular function (Roberts et al 2001). In patients 
with ALI vascular response to oxygen was different and 
administration of 100% O2 worsened intrapulmonary shunt 
possibly secondary to collapse of unstable alveolar units 
with very low ventilation-perfusion (V A/Q) ratios. This is in 
contrast to administration of 100% O2 to patients with COPD, 
in whom only the dispersion of the blood ﬂ  ow distribution 
was changed, suggesting release of hypoxic pulmonary 
vasoconstriction (Santos et al 2000). Optimal supplemental 
oxygen management is an integral component of pulmonary 
hypertension therapy in the ICU (Zamanian et al 2007).
Other treatment options
The observations of a survival advantage in patients with 
pulmonary hypertension and a patent foramen ovale sug-
gested that an intra-atrial right-to-left shunt could decom-
press the RV and increase LV pre-load, thereby increasing 
systemic blood ﬂ  ow and improving systemic oxygen trans-
port despite arterial oxygen desaturation. Atrial septostomy 
has been developed as an alternative/bridge treatment and 
applied in patients with lack of response to medical therapy 
in the absence of other surgical treatment options. It has a 
substantial morbidity and mortality in critically ill patients 
with severe RV failure (Sandoval et al 2001). With grow-
ing experience, procedure-related death rates have been 
reduced to 5.4%, and the most suitable patient group has been 
identiﬁ  ed among patients with a mean right atrial pressure 
between 10 and 20 mm Hg (Klepetko et al 2004). Acute 
right heart failure after orthotopic heart transplantation was 
successfully managed by decompression of the RV through 
the patent foramen ovale of the donor heart and inhalation 
of iloprost (Ozdogan et al 2008). Both pericardiectomy and 
creation of atrial septal defects have been used in extreme 
cases of acute RV failure secondary to acute MI (Reynolds 
and Hochman, 2008). Decompression of the RV through 
the septostomy may potentially be an effective alternative in 
the management of severe acute pulmonary hypertension in 
ICU setting. The defect could be subsequently closed using 
a transcatheter septal occlusion device, after the patient’s 
condition has been stabilized.
In cases of acute right heart failure after heart trans-
plantation, mechanical circulatory support systems, such as 
RV assist devices, extracorporeal membrane oxygenation, 
femoral vein-to-femoral artery roller or centrifugal pumps, 
may facilitate hemodynamic stability until the transplanted Vascular Health and Risk Management 2008:4(5) 1056
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heart has recovered, or until a new heart has been found 
for retransplantation (Aubert et al 2006). They possibly 
could be successfully applied in other cases of potentially 
reversible acute pulmonary hypertension and cor pulmonale. 
Intra-aortic balloon counterpulsation (IABP) has long been 
the mainstay of mechanical therapy for cardiogenic shock. 
Not every patient has a hemodynamic response to IABP 
(Reynolds and Hochman, 2008). However, in patients with 
acute pulmonary hypertension and RV failure associated 
with systemic hypotension it could improve coronary and 
peripheral perfusion and augment LV performance with an 
acute decrease in afterload (Arafa et al 2000).
Conclusion
Many complex medical disorders managed in noncardiac 
ICUs are associated with an elevation of PAP. In some 
circumstances serious and prolonged elevation of PAP pro-
gresses to severe acute pulmonary hypertension, leading to 
life threatening complications including refractory systemic 
arterial hypotension, severe hypoxemia, RV dysfunction 
and failure and ultimately resulting in cardiogenic and/or 
obstructive shock and death. Unfortunately, in most cases 
acute pulmonary hypertension remains under diagnosed and 
its treatment begins only after serious complications have 
developed.
Signiﬁ  cant pathophysiologic differences between acute 
and chronic pulmonary hypertension made current treatment 
recommendations for chronic pulmonary hypertension dif-
ﬁ  cult to apply to acute pulmonary hypertension. Based on 
available data, therapy of acute arterial pulmonary hyper-
tension should be generally aimed at acutely relieving RV 
pressure overload by decreasing PVR and preventing or 
reversing RV dysfunction with pulmonary vasodilators and 
inotropes. Cases of severe acute pulmonary hypertension 
combined with developing heart failure and systemic arte-
rial hypotension are real clinical challenges requiring tight 
hemodynamic monitoring and aggressive treatment including 
combinations of pulmonary vasodilators, inotropic agents 
and systemic arterial vasoconstrictors (see Figure 1). The 
choice of vasopressor and inotropes in patients with acute 
pulmonary hypertension should take in consideration their 
effects on PVR and cardiac output when used alone or in 
combinations with other agents, and must be individualized 
based on individual patient response.
Our review revealed signiﬁ  cant gaps in basic science 
knowledge, clinical studies and management recommendations 
Therapeutic Approach to Arterial Pulmonary Hypertension in ICU
Acute Acute
Arterial Pulmonary Hypertension Arterial Pulmonary Hypertension
Acute on Chronic Acute on Chronic
Arterial Pulmonary Hypertension Arterial Pulmonary Hypertension
1. 1. Hemodynamic monitoring Hemodynamic monitoring
2. 2. Consider PAC vs. serial ECHO Consider PAC vs. serial ECHO
TREAT PRIMARY CAUSE TREAT PRIMARY CAUSE of acute arterial pulmonary hypertension  of acute arterial pulmonary hypertension  FIRST FIRST
Optimize RV Preload Optimize RV Preload Increase/preserve RV Contractility: Increase/preserve RV Contractility:
1. 1. Maintain coronary/systemic perfusion Maintain coronary/systemic perfusion
pressure (target MAP>60 mmHg) pressure (target MAP>60 mmHg)
2. 2. Increase RV contractility/inotropy Increase RV contractility/inotropy
3. 3. Avoid pulmonary vasoconstriction Avoid pulmonary vasoconstriction
4. 4. Maintain cardiac output Maintain cardiac output
Decrease RV Afterload Decrease RV Afterload
IV Fluids IV Fluids
1. Avoid volume overload 1. Avoid volume overload
2. Target CVP 10 2. Target CVP 10–14 mm Hg
Patients with RVH, LVH  Patients with RVH, LVH 
and some pericardial diseases and some pericardial diseases
can tolerate higher CVP can tolerate higher CVP
Vasopressors and Inotropic agents Vasopressors and Inotropic agents
Preferable choice: Preferable choice:
Vasopressin and Norepinephrine Vasopressin and Norepinephrine
With or without Milrinone (or low With or without Milrinone (or low
dose Dobutamine) dose Dobutamine)
Pulmonary Pulmonary
Vasodilators Vasodilators
Preferable choice: Preferable choice:
INO INO + + Sildenafil Sildenafil
Mechanical Mechanical
Ventilation Ventilation
1. O 1. O2 2 supplementation supplementation
(target SpO (target SpO2>95%)
2. Low TV ventilation  2. Low TV ventilation 
Protocol Protocol
3. Maintain Plateau  3. Maintain Plateau 
Pressure <30 mm H2O
Figure 1 Therapeutic approach to arterial pulmonary hypertension in ICU.
Abbreviations: CVP, central venous pressure; ECHO, echocardiogram;  INO, inhaled nitric oxide; IV, intravenous;  LVH, left ventricular hypertrophy; MAP, mean arterial pressure; 
PAC, pulmonary artery catheter; RV, right ventricle; RVH, right ventricular hypertrophy; SpO2, oxygen saturation in the blood; TV, tidal volume.Vascular Health and Risk Management 2008:4(5) 1057
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for acute arterial pulmonary hypertension in the critically ill. 
Intensivists need to be aware of acute pulmonary hypertension 
in critical conditions, the importance of its early recognition 
and appropriate treatment.
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